Trials / Unknown
UnknownNCT01621438
Clinical Implication of 3-vessel Fractional Flow Reserve (FFR)
Influence of Total Atherosclerotic Burden Assessed by 3-vessel Fractional Flow Reserve (FFR) on the Clinical Outcomes of the Patients With Multi-vessel Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,136 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the influence of total atherosclerotic burden assessed by 3-vessel fractional flow reserve (FFR) on the clinical outcomes of the patients with multi-vessel disease. For this purpose, the clinical data of the patients with 3-vessel intermediate coronary artery disease, whose FFR was measured at all 3-vessels due to their own clinical needs, will be analyzed.
Detailed description
Primary Analysis The Primary Analysis will be performed after 2-year follow-up data will be completed. Pre-specified Subgroup Analysis The pre-specified subgroup analysis will perform after 1-year follow-up data will be completed according to the following subjects: * Concordant and discordant results between FFR and angiographic stenosis severity (patients and lesions with pre-PCI FFR will be analyzed.). * Association between total atherosclerotic burden and total ischemic burden, coronary CT angiography substudy (after 2-year follow-up will be completed). * Validation of total ischemic burden (sum of 3 vessel FFR) with Duke score, measured by treadmill test. * Comparison of clinical outcomes of deferred lesions according to pre-PCI FFR levels (Pre-PCI FFR \<0.75, 0.75-0.80, and \>0.80). * Comparison of clinical outcomes of deferred lesions according to iFR and FFR values ⑥ Prognosis of functional complete revascularization versus incomplete revascularization
Conditions
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-03-01
- Completion
- 2018-09-01
- First posted
- 2012-06-18
- Last updated
- 2017-08-25
Locations
20 sites across 5 countries: China, Japan, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01621438. Inclusion in this directory is not an endorsement.